Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lung Neoplasms × zimberelimab × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumor 1 Rectal Neoplasms 1 Oligometastatic Prostate Cancer 1 Neoplasms 1 Metastatic Urothelial Cancer 1 Melanoma 1 Lung Neoplasms 1 Lung Diseases 1 Locally Advanced Cervical Cancer 1 Kidney Neoplasms 1 Gestational Trophoblastic Disease 1 Gastro-enteropancreatic neuroendocrine tumor 1 Erythrocytosis, Familial, 4 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoid Tumor 1 Breast Neoplasms 1 Bile Duct Neoplasms 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 45 Carboplatin 38 Pemetrexed 34 Magnetic Resonance Spectroscopy 33 Specimen Handling 32 Cisplatin 25 Blood Specimen Collection 20 Paclitaxel 15 Radiosurgery 14 durvalumab 13 Radiotherapy 13 Gemcitabine 12 Bevacizumab 12 osimertinib 11 atezolizumab 11 Biopsy 11 Practice Guidelines as Topic 10 Nivolumab 10 Educational Status 9 130-nm albumin-bound paclitaxel 9 X-Rays 8 Standard of Care 8 Immunoglobulin G 8 Docetaxel 8 Surveys and Questionnaires 7 Disulfides 7 Cetuximab 7 Taxes 6 Etoposide 6 Drug Therapy 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05633667 2026-03-17

VELOCITY-Lung

Gilead Sciences

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡